CN113924145A - 痛风或高尿酸血症的治疗药 - Google Patents

痛风或高尿酸血症的治疗药 Download PDF

Info

Publication number
CN113924145A
CN113924145A CN202080040395.1A CN202080040395A CN113924145A CN 113924145 A CN113924145 A CN 113924145A CN 202080040395 A CN202080040395 A CN 202080040395A CN 113924145 A CN113924145 A CN 113924145A
Authority
CN
China
Prior art keywords
pharmaceutical composition
pharmaceutically acceptable
administration
acceptable salt
general formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202080040395.1A
Other languages
English (en)
Chinese (zh)
Inventor
小林四郎
宫山绘里
平野益治
太田隆
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nippon Chemiphar Co Ltd
Original Assignee
Nippon Chemiphar Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nippon Chemiphar Co Ltd filed Critical Nippon Chemiphar Co Ltd
Publication of CN113924145A publication Critical patent/CN113924145A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN202080040395.1A 2019-06-04 2020-06-04 痛风或高尿酸血症的治疗药 Pending CN113924145A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2019-104534 2019-06-04
JP2019104534 2019-06-04
PCT/JP2020/022039 WO2020246528A1 (ja) 2019-06-04 2020-06-04 痛風又は高尿酸血症の治療薬

Publications (1)

Publication Number Publication Date
CN113924145A true CN113924145A (zh) 2022-01-11

Family

ID=73653292

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080040395.1A Pending CN113924145A (zh) 2019-06-04 2020-06-04 痛风或高尿酸血症的治疗药

Country Status (8)

Country Link
US (1) US20220323441A1 (https=)
EP (1) EP3981469B1 (https=)
JP (2) JPWO2020246528A1 (https=)
KR (1) KR20220016861A (https=)
CN (1) CN113924145A (https=)
AU (1) AU2020287549B2 (https=)
CA (1) CA3149714A1 (https=)
WO (1) WO2020246528A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN121648131A (zh) * 2020-12-08 2026-03-13 学校法人东日本学园 细胞内atp增强剂

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1757610T3 (da) * 2004-06-14 2011-08-01 Nippon Chemiphar Co Kondenseret pyrimidinderivat og xanthinoxidaseinhibitor
CN105579037A (zh) * 2013-05-31 2016-05-11 武田制药美国有限公司 用黄嘌呤氧化酶抑制剂治疗的方法和含黄嘌呤氧化酶抑制剂的组合物
TWI780270B (zh) * 2017-11-28 2022-10-11 靜岡縣公立大學法人 固體分散體
JP2019104534A (ja) 2017-12-13 2019-06-27 大日本印刷株式会社 ロール体梱包箱
JP2021127289A (ja) * 2018-04-27 2021-09-02 日本ケミファ株式会社 縮合ピリミジン誘導体

Also Published As

Publication number Publication date
WO2020246528A1 (ja) 2020-12-10
AU2020287549B2 (en) 2026-01-29
CA3149714A1 (en) 2020-12-10
KR20220016861A (ko) 2022-02-10
AU2020287549A1 (en) 2022-01-27
JP2025061775A (ja) 2025-04-11
EP3981469A1 (en) 2022-04-13
EP3981469B1 (en) 2024-11-20
JPWO2020246528A1 (https=) 2020-12-10
US20220323441A1 (en) 2022-10-13
EP3981469A4 (en) 2023-06-21

Similar Documents

Publication Publication Date Title
CN103228277B (zh) 难溶性药物的溶解性改善制剂
TWI780270B (zh) 固體分散體
JP2025061775A (ja) 痛風又は高尿酸血症の治療薬
TWI615157B (zh) 包括不定形西洛他唑的固體分散劑
CN116528840B (zh) 细胞内atp增强剂
WO2019230937A1 (ja) 溶出性に優れた経口固形製剤
JP6903252B2 (ja) キサンチンオキシダーゼ阻害剤含有腸溶性製剤
HK40098529A (zh) 固体分散体
HK40073463A (en) Therapeutic for gout or hyperuricemia
HK40073463B (en) Therapeutic for gout or hyperuricemia
HK40027115B (zh) 固体分散体
HK40027115A (en) Solid dispersion
JP2025524090A (ja) ｎｏｒ－ＵＤＣＡの医薬組成物
CN118526459A (zh) 一种达罗他胺固分体及其制备方法
US20240277726A1 (en) Pharmaceutical composition comprising meloxicam
BRPI0607372B1 (pt) Medicamento destinado à administração oral, compreendendo um inibidor da ciclooxigenase-2, e método de preparação do mesmo
JP2008162949A (ja) チアゾリジンジオン化合物を含有する糖尿病治療薬

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination